It's not just how much money that is being raised by psychedelic drug companies. It's HOW they are doing it.
Exploring the companies and themes that make up this emerging and exciting new sector
MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category
Mind Cure announces plans to roll out a line of pre- and post-treatment adaptogen supplements.
Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US
Field Trip continues its U.S. expansion with opening of a new clinic in Atlanta.
Re-Release: Psyched Wellness Upsizes Previously Announced Bought Deal Offering
Psyched Wellness increases its bought deal offering from CAD$3 million to CAD$5.5 million.
How the psychedelic Ibogaine helped a retired Vancouver firefighter treat his depression
In an interview with City News, a retired firefighter and rescue member from Vancouver says that Iboga, a psychedelic rainforest shrub that grows across West Africa, saved his life.
Cannabis compliance firm Allay Consulting adds psilocybin offering
Allay Consulting, a Portland, OR-based firm specializing in cannabis regulatory compliance consulting, has announced a new division to deliver regulatory compliance services in the legal therapeutic psilocybin market in Oregon, as well as other jurisdictions that follow suit.
Beckley Foundation: The Major Psychedelics Non-Profit Across The Pond
The UK-based Beckley Foundation is a psychedelics non-profit founded over 20 years ago that is having an increasing impact on the Psychedelics Revolution.
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
Mind Cure has upsized its bought deal financing by DOUBLE to CAD$20 million.
Numinus Announces Listing of New Warrants
Numinus announces the listing of its latest series of warrants for public trading, under the symbol "NUMI.WS". Warrants have an exercise price of CAD$0.90 and are valid until December 29, 2022.
Albert Labs inks LOI to undergo reverse takeover of ME Resource in move to expand access to psychedelics
Albert Labs, a privately held psychedelic drug developer, signed a letter of intent (LOI) on January 5 to be acquired by ME Resource Corp (CSE:MEC) (OTC:MEEXF), the latter company announced.
Psyched Wellness Announces C$3M Bought Deal Private Placement Led by Canaccord Genuity
Psyched Wellness announces a CAD$3 million bought deal with units priced at CAD$0.31.
The first-ever psychedelics ETF will launch next week, backed by a Canadian fund manager
The first-ever psychedelics ETF will begin trading on the Canadian NEO exchange next Wednesday, giving investors exposure to publicly-traded companies focused on the development of therapeutic solutions that utilize psychedelics.